Related Experiment Video
Updated: Feb 11, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as
Olli Dufva1, Matti Kankainen2,3, Tiina Kelkka1
1Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, FIN-00290, Helsinki, Finland.
Abstract:
Aggressive natural killer-cell (NK-cell) leukemia (ANKL) is an extremely aggressive malignancy with dismal prognosis and lack of targeted therapies. Here, we elucidate the molecular pathogenesis of ANKL using a combination of genomic and drug sensitivity profiling. We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations in STAT3 (21%) and RAS-MAPK pathway genes (21%) as well as in DDX3X (29%) and epigenetic modifiers (50%). Additional alterations include JAK-STAT copy gains and tyrosine phosphatase mutations, which we show recurrent also in extranodal NK/T-cell lymphoma, nasal type (NKTCL) through integration of public genomic data. Drug sensitivity profiling further demonstrates the role of the JAK-STAT pathway in the pathogenesis of NK-cell malignancies, identifying NK cells to be highly sensitive to JAK and BCL2 inhibition compared to other hematopoietic cell lineages. Our results provide insight into ANKL genetics and a framework for application of targeted therapies in NK-cell malignancies.
Insights
Aggressive natural killer-cell leukemia (ANKL) genetics reveal key mutations in STAT3, RAS-MAPK, DDX3X, and epigenetic modifiers. NK cells show sensitivity to JAK and BCL2 inhibition, offering new therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Aggressive natural killer-cell leukemia (ANKL) is a rare and aggressive cancer with poor outcomes.
- Current treatment options for ANKL are limited, highlighting the need for targeted therapies.
Purpose of the Study:
- To elucidate the molecular pathogenesis of ANKL through comprehensive genomic and drug sensitivity profiling.
- To identify potential therapeutic targets for ANKL and related NK-cell malignancies.
Main Methods:
- Whole-exome sequencing (WES) was performed on 14 ANKL patient samples.
- Genomic data from public databases were integrated to identify recurrent alterations.
- Drug sensitivity profiling was conducted to assess the response of NK cells to targeted inhibitors.
Main Results:
- Mutations were identified in STAT3 (21%), RAS-MAPK pathway genes (21%), DDX3X (29%), and epigenetic modifiers (50%).
- JAK-STAT copy gains and tyrosine phosphatase mutations were found to be recurrent in ANKL and extranodal NK/T-cell lymphoma, nasal type (NKTCL).
- NK cells demonstrated high sensitivity to JAK and BCL2 inhibition compared to other hematopoietic cell lineages.
Conclusions:
- The study provides critical insights into the genetic landscape of ANKL.
- Identified genetic alterations and drug sensitivities offer a framework for developing targeted therapies for ANKL and other NK-cell malignancies.
Related Concept Videos
The JAK-STAT Signaling Pathway
Aggression
Mutations
What is Cell Signaling?
Viral Mutations
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

